5,168 results match your criteria European journal of haematology[Journal]


Primary Immune Thrombocytopenia (ITP) Treated with Romiplostim in Routine Clinical Practice: Retrospective Study from the United Kingdom ITP Registry.

Eur J Haematol 2019 Feb 13. Epub 2019 Feb 13.

Barts and The London School of Medicine and Dentistry, London, United Kingdom.

Background: Romiplostim is a thrombopoietin-mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts, and romiplostim usage in UK clinical practice.

Methods: This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13221DOI Listing
February 2019

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.

Eur J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Objective: This prospective, observational, postmarketing surveillance was conducted to evaluate the safety and effectiveness of mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, in patients with CCR4-positive, relapsed or refractory (r/r) adult T-cell leukemia-lymphoma (ATL) in Japan.

Method: All patients were scheduled to receive intravenous infusions of mogamulizumab 1.0 mg/kg once weekly for 8 weeks, alone or in combination with other modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13220DOI Listing
February 2019
2 Reads

Stratification by MYC expression has prognostic impact in MYC/BCL2 translocated B-cell lymphoma - identifies a subgroup of patients with poor outcome.

Eur J Haematol 2019 Feb 9. Epub 2019 Feb 9.

Dept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.

Objective: In patients with Large B-cell Lymphoma (LBCL) according to WHO the prognostic significance of MYC translocation is still not sufficiently clarified. We therefore aimed to investigate whether prognostication could be improved in patients with MYC translocation positive LBCL by additional stratification according to MYC and BCL2 protein expression levels or MYC translocation partner gene as well as concurrent BCL2 and/or BCL6 translocation (DH).

Methods: From an unselected consecutive cohort of >600 patients with LBCL investigated with fluorescent in situ hybridization (FISH) 64 patients were diagnosed with MYC translocation positive LBCL and included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13219DOI Listing
February 2019
1 Read

Durable Remissions With Venetoclax Monotherapy in Secondary AML Refractory to Hypomethylating Agents and High Expression of BCL-2 and/or BIM.

Eur J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria.

Secondary acute myeloid leukemia (sAML) evolving from an antecedent hematological disorder and therapy-related sAML represent high-risk subsets of AML and are associated with poor clinical outcome. The hypomethylating agents (HMA), azacitidine and decitabine represent treatment options for elderly AML patients including sAML patients unfit for intensive chemotherapy. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13218DOI Listing
February 2019

Pomalidomide-Dexamethasone for Treatment of Soft Tissue Plasmacytomas in Patients with relapsed / refractory Multiple Myeloma.

Eur J Haematol 2019 Feb 5. Epub 2019 Feb 5.

Hospital Clinic, IDIBAPS, Barcelona.

Objective: The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedulary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide-dexamethasone combination in this patient profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13217DOI Listing
February 2019

Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.

Eur J Haematol 2019 Jan 31. Epub 2019 Jan 31.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Objective: In individuals with cytogenetically normal (CN) AML, disease risk is estimated using molecular features such as the status of NPM1 and FLT3-ITD genes. However, data regarding the impact of NPM1 and FLT3-ITD status on hematopoietic stem cell transplant (HCT) outcomes are limited. We examined the effect of NPM1 and FLT3-ITD status on transplant outcomes in 131 CN AML patients transplanted at Princess Margaret Hospital between 2006 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13216DOI Listing
January 2019
1 Read

Risks and challenges of CML management during pregnancy: Looking for a balanced decision.

Eur J Haematol 2019 Jan 23. Epub 2019 Jan 23.

National Research Center for Hematology, Moscow, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13215DOI Listing
January 2019

Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.

Eur J Haematol 2019 Jan 23. Epub 2019 Jan 23.

Bone Marrow Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy.

Objectives: T-cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) is at high risk of invasive fungal infections (IFI), and anti-mold-active drug is required for primary antifungal prophylaxis (PAP) according to international guidelines. No data are available on the efficacy of caspofungin as PAP in this setting.

Methods: Here, we report our retrospective experience with 103 consecutive patients treated with caspofungin as PAP after Haplo-SCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13214DOI Listing
January 2019
1 Read

Fulminant Hepatitis Associated Liver Failure and Aplastic Anaemia Managed With Sequential Liver and Haematopoietic Stem Cell Transplantation.

Eur J Haematol 2019 Jan 22. Epub 2019 Jan 22.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

The management of Severe Aplastic Anaemia is particularly challenging when it occurs in the context of recent liver transplantation. Rapid identification of a suitable donor followed by allogeneic haematopoietic stem cell transplantation is the only curative option. This scenario is often complicated by potentially life threatening infections that develop as a consequence of immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13213DOI Listing
January 2019
1 Read

Single versus double-unit transfusion: Safety and efficacy for patients with hematologic malignancies.

Eur J Haematol 2019 Jan 21. Epub 2019 Jan 21.

Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.

Objectives: Although hemoglobin thresholds for red blood cell (RBC) transfusion have decreased, double-unit RBC transfusion practices persist. We studied the effects switching from predominantly double-unit to single-unit RBC transfusions had on utilization and clinical outcomes for malignant hematology patients.

Methods: Retrospective chart review compared malignant hematology patients before and after implementing single-unit RBC transfusion policy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13211
Publisher Site
http://dx.doi.org/10.1111/ejh.13211DOI Listing
January 2019
2 Reads

Insight into the complex pathophysiology of sickle cell anemia and possible treatment.

Eur J Haematol 2019 Jan 21. Epub 2019 Jan 21.

Dept of Paediatric Haematology, Our Lady's Children's Hospital, Dublin, Ireland.

Sickle cell anaemia (SCA) is the consequence of abnormal haemoglobin production due to an inherited point mutation in the β -globin gene. The resulting haemoglobin tetramer is poorly soluble when deoxygenated, and when this is prolonged, intracellular gelation of sickle haemoglobin occurs, followed by haemoglobin polymerization. If many cycles of sickling and unsickling occur, the red cell membrane will be disrupted leading to haemolysis and vaso-occlusive events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13212DOI Listing
January 2019
2 Reads
2.066 Impact Factor

Corrigendum.

Authors:

Eur J Haematol 2019 Jan 20. Epub 2019 Jan 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13195DOI Listing
January 2019

Bleeding Assessment in female patients with the Hermansky-Pudlak syndrome - A Case Series.

Eur J Haematol 2019 Jan 19. Epub 2019 Jan 19.

Department of Surgery, School of Medicine, Medical Sciences Campus, Universityof Puerto Rico.

The Hermansky-Pudlak syndrome (HPS) is a genetically heterogeneous group of autosomal recessive disorders characterized by: oculocutaneous albinism (OCA); bleeding diathesis; and other systemic complications including: chronic granulomatous colitis, and pulmonary fibrosis. Despite HPS being a rare genetic disease worldwide, it is the most common single-gene disorder in the island of Puerto Rico (PR), particularly in the northwestern region, where it occurs with a frequency of 1:1,800 and where carrier frequency is estimated to be 1 out of 21 citizens. HPS thus represents a significant public health issue in PR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13210DOI Listing
January 2019

Common oral diseases in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pre-HSCT.

Eur J Haematol 2019 Jan 11. Epub 2019 Jan 11.

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Objectives: The purpose of this study was to compare the prevalence of common oral diseases between allogeneic haematopoietic stem cell transplantation (HSCT) recipients and healthy controls.

Materials And Methods: A total of 143 adult allogeneic HSCT recipients who were treated for haematological malignancies between 2008 and 2016 were included in the study. The HSCT recipients were age and sex matched with healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13209DOI Listing
January 2019

The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature.

Eur J Haematol 2018 Dec 28. Epub 2018 Dec 28.

The Division of Hematology & Oncology, School of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Direct oral anticoagulants (DOACs) have been shown to be superior to vitamin K antagonists (VKAs) in regards to safety and efficacy in numerous clinical trials and are now the preferred oral anticoagulant by multiple professional societies. However, patients with significant levels of organ dysfunction were excluded from all major clinical trials, leaving the clinical benefit in these subsets uncertain. Patients with chronic kidney disease (CKD) specifically often require anticoagulation for acute or long-term indications such as venous thromboembolism, atrial fibrillation, or mechanical heart valves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13208DOI Listing
December 2018
1 Read

Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.

Eur J Haematol 2018 Dec 22. Epub 2018 Dec 22.

Astellas Pharma US, Inc., Northbrook, Illinois.

Objectives: To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated (FLT3 ) and FLT3-wild-type (FLT3 ) acute myeloid leukemia (AML).

Methods: Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ≥65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13205DOI Listing
December 2018

Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patients.

Eur J Haematol 2019 Mar 17;102(3):265-274. Epub 2019 Jan 17.

Department of Haematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Duesseldorf, Duesseldorf, Germany.

Objective: We evaluated the development of ICU survival of patients with hematopoietic malignancies and discussed changes in admittance policies.

Method: We compared 166 patients treated between 2009 and 2012 with 138 patients treated between 2013 and 2016. Patient characteristics and outcome were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13206DOI Listing
March 2019
2 Reads

Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.

Eur J Haematol 2019 Mar 16;102(3):203-209. Epub 2019 Jan 16.

Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

The molecular pathogenesis of deletion 5q (del(5q)) myelodysplastic syndrome (MDS) has recently been realized as a result of major advances in our understanding of the mechanisms responsible for clinical phenotype. Identification of commonly deleted genes such as RPS14, miRNA-145, HSPA9, CD78, and CSNK1a1 have elucidated the precise biological changes responsible for the anemia, leukopenia, and thrombocytosis that characterizes del(5q) MDS and highlighted the importance of allelic haploinsufficiency in the hematological phenotype. Recent elegant investigations have also identified a critical role of innate immune signaling in del(5q) pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13207DOI Listing
March 2019
2 Reads

Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.

Eur J Haematol 2019 Mar 9;102(3):256-264. Epub 2019 Jan 9.

Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Objectives: To establish the optimal strategy for haploidentical hematopoietic stem cell transplantation (HSCT).

Methods: We performed a prospective study on haploidentical HSCT using low-dose alemtuzumab. Alemtuzumab was added at 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13204
Publisher Site
http://dx.doi.org/10.1111/ejh.13204DOI Listing
March 2019
5 Reads

Haematological malignancy: are we measuring what is important to patients? A systematic review of quality of life instruments.

Eur J Haematol 2018 Dec 16. Epub 2018 Dec 16.

School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.

The wide range of health-related quality of life (HRQoL) instruments used in haematology makes it challenging for haematologists and other care team members in practice to select, use and understand the scoring system and finally interpret the results. The main objectives of this study were to: (I) identify quality of life issues important to patients suffering from haematological malignancies (HM); (ii) identify HRQoL instruments used in HMs; and (iii) examine the suitability and validity of the identified instruments in HMs. Systematic literature review of two data bases, followed by addition of articles by manual searching was carried out. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13203DOI Listing
December 2018

Corrigendum.

Authors:

Eur J Haematol 2019 Jan 19;102(1):99. Epub 2018 Nov 19.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13181DOI Listing
January 2019

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen.

Eur J Haematol 2018 Dec 1. Epub 2018 Dec 1.

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Objective: Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT).

Method: We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months.

Results: Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13202DOI Listing
December 2018
1 Read

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Eur J Haematol 2019 Feb 28;102(2):182-190. Epub 2018 Nov 28.

Department of Hematology, Rigshospitalet, Copenhagen, Denmark.

Objectives: Infections pose the greatest risk of early death in patients with Multiple Myeloma. However, few studies have analyzed the risk factors for infections in Multiple Myeloma patients. The aim of this study was to analyze the risk factors infections within a population-based MM cohort. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13190
Publisher Site
http://dx.doi.org/10.1111/ejh.13190DOI Listing
February 2019
3 Reads

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.

Eur J Haematol 2019 Mar 1;102(3):235-240. Epub 2019 Jan 1.

Hematology Section, Specialist Medicine, NU Hospital Group, Uddevalla, Sweden.

Objectives: The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia.

Methods: A cross-sectional study of 80 MF and 23 ET patients was performed.

Results: About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation <20 and normal or elevated S-ferritin (<500 µg/L). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13198DOI Listing
March 2019
8 Reads

Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.

Eur J Haematol 2019 Mar 20;102(3):241-250. Epub 2019 Jan 20.

Department of Haematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Objectives: The GMALL-B-ALL/NHL2002 protocol is effective in Burkitt lymphoma/leukemia (BL). Its role in other aggressive lymphomas and in patients with simultaneous central nervous system (CNS) and peripheral involvement is unclear.

Methods: This is a retrospective outcome analysis in 76 patients with BL (n = 26), B-lymphoblastic lymphoma (B-LBL; n = 3), diffuse large B-cell lymphoma (DLBCL; n = 31), mantle cell lymphoma (MCL; n = 6), transformed B-cell non-Hodgkin lymphomas (tB-NHL; n = 7), and T-cell NHL (T-NHL; n = 3) treated with the GMALL-B-ALL/NHL2002 protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13199DOI Listing
March 2019
14 Reads

CTLA-4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood.

Eur J Haematol 2019 Mar 7;102(3):251-255. Epub 2019 Jan 7.

Department of Pediatrics, Jena University Hospital, Jena, Germany.

Objective: Relapse following allogeneic hematopoietic stem cell transplantation (HSCT) is still linked to a poor prognosis. Mainly, donor`s T-cells mediate the graft-versus-leukemia effect. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule which down-regulates T-cell activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13200DOI Listing
March 2019
7 Reads

Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.

Eur J Haematol 2019 Mar 10;102(3):227-234. Epub 2019 Jan 10.

Department of Haematology, Odense University Hospital, Odense, Denmark.

Objective: Pulmonary hypertension (PH) has been reported to be associated with myeloproliferative neoplasms (MPN), affecting 5%-48% of MPN patients. With the aims to describe the prevalence of PH in Ph-MPN patients and explore the cause in identified subjects, we performed a prospective cohort study of Ph-MPN patients.

Method: Transthoracic echocardiography (TTE) was performed on all patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13197
Publisher Site
http://dx.doi.org/10.1111/ejh.13197DOI Listing
March 2019
10 Reads

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.

Eur J Haematol 2019 Mar 22;102(3):218-226. Epub 2019 Jan 22.

Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.

Objective: Short telomere length is a known risk factor for developing clonal haematopoietic stem cell disorders, probably due to chromosomal instability. We tested the hypotheses that bone marrow mononuclear cell telomere length change from diagnosis through chemotherapy-induced remission and relapse, and that long telomere length is associated with low risk of relapse and all-cause mortality in patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome.

Methods: We measured telomere length in bone marrow mononuclear cells from 233 patients at diagnosis, 112 patients at chemotherapy-induced remission and 58 patients at relapse of disease. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13196
Publisher Site
http://dx.doi.org/10.1111/ejh.13196DOI Listing
March 2019
1 Read

Current practices in the management of adenovirus infection in allogeneic hematopoietic stem cell transplant recipients in Europe: The AdVance study.

Eur J Haematol 2019 Mar 11;102(3):210-217. Epub 2019 Jan 11.

Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.

Objective: Adenovirus (AdV) infections are potentially life-threatening for allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. The AdVance study aimed to evaluate the incidence, management, and outcomes of AdV infections in European allo-HCT recipients.

Methods: As part of the study, physician surveys were conducted to determine current AdV screening and treatment practices at their center. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13194
Publisher Site
http://dx.doi.org/10.1111/ejh.13194DOI Listing
March 2019
13 Reads

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Eur J Haematol 2019 Feb 6;102(2):111-122. Epub 2018 Dec 6.

Foundation IRCCS Cà Granda, Maggiore Hospital Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside higher treatment-related costs. Bypassing agents can be used to prevent and control bleeding, as well as the recently licensed prophylaxis, emicizumab, but their efficacy is less predictable than that of factor replacement therapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13193
Publisher Site
http://dx.doi.org/10.1111/ejh.13193DOI Listing
February 2019
15 Reads

Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia.

Eur J Haematol 2019 Feb 29;102(2):197-199. Epub 2018 Nov 29.

Memorial Sloan Kettering Cancer Center, New York City, New York.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13192
Publisher Site
http://dx.doi.org/10.1111/ejh.13192DOI Listing
February 2019
14 Reads

CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.

Eur J Haematol 2019 Feb 23;102(2):191-196. Epub 2018 Nov 23.

Department of Laboratory Molecular Genetics of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Objective: Primary vitreoretinal lymphoma (PVRL) is a rare type of lymphoma wherein the lesions are limited to the eyes. PVRL is difficult to diagnose because of the challenges related to obtaining sufficient samples for biopsy. Moreover, PVRL has poor outcomes and often leads to the development of central nervous system (CNS) lesions during its course. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13191
Publisher Site
http://dx.doi.org/10.1111/ejh.13191DOI Listing
February 2019
12 Reads

Molecular pathogenesis of acquired aplastic anemia.

Eur J Haematol 2019 Feb 18;102(2):103-110. Epub 2018 Dec 18.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

The application of next-generation sequencing (NGS) has enhanced our understanding of the genetic landscape in acquired aplastic anemia (AA). Parallel progress has been in addressing aspects underlying immune dysregulation in disease pathogenesis. Novel insights into the molecular and biologic mechanisms have led to a shift in the paradigm of AA, from a solely autoimmune pathogenic concept toward its recognition as a multifaceted pathophysiology characterized by cytogenetic abnormalities, recurrent somatic mutations, telomere attrition, and immune dysregulation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13182
Publisher Site
http://dx.doi.org/10.1111/ejh.13182DOI Listing
February 2019
5 Reads

Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.

Eur J Haematol 2019 Feb 29;102(2):157-162. Epub 2018 Nov 29.

Section of Hematology and Medical Oncology, Tulane University, New Orleans, Louisiana.

Background: Immune checkpoint inhibitors (CPI) are widely used in modern oncology and have improved the prognosis of lung cancer, malignant melanoma, and other malignancies. Unlike cytotoxic chemotherapy, drugs such as nivolumab, pembrolizumab, and ipilimumab are associated with immune-related adverse effects. We recently observed a patient with lung cancer who developed a fulminant warm antibody autoimmune hemolytic anemia (AIHA). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13187
Publisher Site
http://dx.doi.org/10.1111/ejh.13187DOI Listing
February 2019
9 Reads

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

Eur J Haematol 2019 Feb 7;102(2):163-173. Epub 2019 Jan 7.

Department of Internal Medicine I, University Hospital Cologne, Köln, Germany.

Objectives: Domatinostat (4SC-202) is a selective class I histone deacetylase inhibitor (HDACi). This phase I study investigated safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity in patients with advanced hematological malignancies.

Methods: Domatinostat was administered orally once (QD) or twice daily (BID) on days 1-14 with 7 days off or continuously days 1-21 in a 3 + 3 design at 7 dose levels from 25 to 400 mg total daily dose (TDD). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13188
Publisher Site
http://dx.doi.org/10.1111/ejh.13188DOI Listing
February 2019
15 Reads

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Eur J Haematol 2019 Feb 23;102(2):174-181. Epub 2018 Nov 23.

Outpatient Center for Hematology, Oncology and Gastroenterology, Singen, Germany.

Objective: The prospective non-interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex ), a glycopegylated granulocyte colony-stimulating factor, in cancer patients with different tumor entities undergoing chemotherapy in routine clinical practice. The primary objective was incidence of severe neutropenia, febrile neutropenia (FN), and neutropenia-associated complications.

Method: NADIR was a national, multicenter, prospective NIS. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13189
Publisher Site
http://dx.doi.org/10.1111/ejh.13189DOI Listing
February 2019
11 Reads

Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety.

Eur J Haematol 2019 Feb 28;102(2):150-156. Epub 2018 Nov 28.

King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.

Objectives: Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment-sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).

Methods: We collected published data of patients undergoing allogeneic HSCT after treatment with CPIs (cohort 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13186DOI Listing
February 2019

Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.

Eur J Haematol 2019 Feb 20;102(2):143-149. Epub 2018 Nov 20.

Evidence-Based Practice Center, UCONN/Hartford Hospital, Hartford, Connecticut.

Objectives: To assess the association between rivaroxaban and warfarin and major bleeding risk in unprovoked venous thromboembolism (VTE) patients.

Methods: Using US MarketScan claims from 1/2012-12/2016, we identified patients who had ≥1 primary hospitalization/emergency department visit diagnosis code for an unprovoked VTE, newly initiated on rivaroxaban or warfarin within 30 days after the VTE and ≥12 months of insurance coverage prior to the VTE. Differences in baseline covariates were adjusted using inverse-probability-of-treatment weights based on propensity scores (residual absolute standardized differences <0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13185DOI Listing
February 2019
2 Reads

Danazol as a second-line treatment for immune thrombocytopenic purpura.

Authors:
Jacques Zimmer

Eur J Haematol 2019 Jan 9;102(1):97-98. Epub 2018 Nov 9.

Department of Infection and Immunity, Luxembourg Institute of Health, House of BioHealth, Esch-sur-Alzette, Luxembourg.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13184
Publisher Site
http://dx.doi.org/10.1111/ejh.13184DOI Listing
January 2019
2 Reads

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Eur J Haematol 2019 Feb 28;102(2):131-142. Epub 2018 Nov 28.

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

Objectives: We previously reported the prognostic value of serum ferritin in younger patients with intermediate-risk acute myeloid leukemia (AML). The aims of this study were to confirm this finding in a larger cohort regardless of age and prognostic subgroups, to explore the expression and functional role of ferritin in AML cells as well as the regulation of serum ferritin levels in AML patients.

Patients/materials/methods: Serum ferritin levels at diagnosis were collected in a cohort of 525 patients treated by intensive chemotherapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13183
Publisher Site
http://dx.doi.org/10.1111/ejh.13183DOI Listing
February 2019
13 Reads

Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).

Eur J Haematol 2019 Feb 9;102(2):123-130. Epub 2018 Dec 9.

Erciyes University Medical Faculty, Kayseri, Turkey.

Objectives: To evaluate the long-term efficacy and safety of deferasirox therapy in a large observational cohort of children with transfusion-dependent thalassemia (TDT) and sickle cell anemia (SCA) in Turkey.

Methods: This was a multicenter, prospective cohort study including TDT and SCA patients aged 2-18 years with iron overload (≥100 mL/kg of pRBC or a serum ferritin [SF] level >1000 μg/L) receiving deferasirox. Patients were followed for up to 3 years according to standard practice. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13180
Publisher Site
http://dx.doi.org/10.1111/ejh.13180DOI Listing
February 2019
19 Reads
2.066 Impact Factor

Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.

Eur J Haematol 2019 Jan 22;102(1):87-96. Epub 2018 Nov 22.

Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota.

Objective: Acute myeloid leukemia (AML) can be subtyped based on recurrent cytogenetic and molecular genetic abnormalities with diagnostic and prognostic significance. Although cytogenetic characterization classically involves conventional chromosome and/or fluorescence in situ hybridization (FISH) assays, limitations of these techniques include poor resolution and the inability to precisely identify breakpoints.

Method: We evaluated whether an NGS-based methodology that detects structural abnormalities and copy number changes using mate pair sequencing (MPseq) can enhance the diagnostic yield for patients with AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13179DOI Listing
January 2019
15 Reads

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.

Eur J Haematol 2019 Jan 22;102(1):79-86. Epub 2018 Nov 22.

ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Objective And Methods: Pediatric-inspired regimens have been adopted by several groups as the treatment strategy for adult patients with acute lymphoblastic leukemia (ALL). Whether subsequent modifications of these protocols have led to an improvement in the outcome of patients is uncertain, especially in T-cell ALL. We analyzed 169 patients with high-risk T-cell ALL included in two consecutive trials of the PETHEMA Group (HR-ALL03 [n = 104] and the more contemporary HR-ALL11 [n = 65]). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13178DOI Listing
January 2019
8 Reads

Venous thrombosis in unusual sites: A practical review for the hematologist.

Eur J Haematol 2019 Jan 29;102(1):53-62. Epub 2018 Oct 29.

Division of Hematology-Oncology, Oregon Health & Science University, Portland, Oregon.

Thrombosis of unusual venous sites encompasses a large part of consultative hematology and is encountered routinely by practicing hematologists. Contrary to the more commonly encountered lower extremity venous thrombosis and common cardiovascular disorders, the various thromboses outlined in this review have unique presentations, pathophysiology, workup, and treatments that all hematologists should be aware of. This review attempts to outline the most up to date literature on cerebral, retinal, upper extremity, hepatic, portal, splenic, mesenteric, and renal vein thrombosis, focusing on the incidence, pathophysiology, provoking factors, and current recommended treatments for each type of unusual thrombosis to provide a useful and practical review for the hematologist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13177DOI Listing
January 2019
10 Reads

How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry.

Eur J Haematol 2019 Jan 25;102(1):36-52. Epub 2018 Oct 25.

Division of Hematology & Thromboembolism, McMaster University, Hamilton, Ontario, Canada.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease characterized by intravascular hemolysis, thrombophilia, and marrow failure. Its phenotype is due to absent or reduced expression of GPI-linked complement regulators and subsequent sensitivity of hematopoietic cells to complement-mediated damage and lysis. Introduction of the terminal complement inhibitor eculizumab drastically improved outcomes in PNH patients; however, despite this improvement, there remain several challenges faced by PNH patients and physicians who care for them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13176DOI Listing
January 2019
10 Reads

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.

Eur J Haematol 2019 Jan 29;102(1):70-78. Epub 2018 Oct 29.

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.

Objectives: The Danish Myeloma Study Group initiated a randomized, placebo-controlled, double-blinded phase II study to investigate the efficacy of adding clarithromycin to cyclophosphamide-bortezomib-dexamethasone (VCD) induction therapy in transplant eligible, newly diagnosed multiple myeloma patients. The study was prematurely terminated due to severe complications, and no effect of adding clarithromycin was found. The aim of this study was to compare health-related quality of life (HRQoL) between the two groups and to explore the coherence hereof with adverse event (AE) registration by clinicians. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13175
Publisher Site
http://dx.doi.org/10.1111/ejh.13175DOI Listing
January 2019
5 Reads

Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.

Eur J Haematol 2019 Jan 14;102(1):63-69. Epub 2018 Nov 14.

Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.

Objective: We report cases of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) with trisomy 8 associated with inflammatory and autoimmune diseases (IADs).

Method: Data for 21 patients with trisomy 8-MDS/MPN and IADs were analyzed and compared to 103 patients with trisomy 8-MDS/MPN without IADs.

Results: The median age of MDS/MPN patients with IADs was 67 [59-80]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13174DOI Listing
January 2019
8 Reads

Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.

Eur J Haematol 2018 Dec 9;101(6):798-803. Epub 2018 Oct 9.

Laboratoire LIBM EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Villeurbanne, France.

Objective: Determine the effect of fetal hemoglobin (HbF) and α-thalassemia on red blood cell (RBC) deformability of patients with sickle-cell anemia (SCA) with and without hydroxyurea (HU).

Methods: Adult patients were enrolled in the Sickle Cell Program of the Cardeza Foundation (Thomas Jefferson University) and were followed up prospectively during the period in which the Multicenter Study of Hydroxyurea (MSH) in patients with SCA was conducted. Ninety-one patients did not receive HU, 20 patients were enrolled in MSH, and 10 patients were enrolled in an open-label study of HU in SCA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224298PMC
December 2018
47 Reads

Clinical implications of molecular markers in acute myeloid leukemia.

Eur J Haematol 2019 Jan 23;102(1):20-35. Epub 2018 Oct 23.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13172DOI Listing
January 2019
18 Reads

Anticoagulation in the cardiac patient: A concise review.

Eur J Haematol 2019 Jan 14;102(1):3-19. Epub 2018 Nov 14.

The Division of Hematology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Anticoagulation has multiple roles in the treatment of cardiovascular disease, including in management of acute myocardial infarction, during percutaneous coronary intervention, as stroke prophylaxis in patients with atrial arrhythmias, and in patients with mechanical heart valves. Clinical anticoagulation choices in the aforementioned diseases vary widely, due to conflicting data to support established agents and the rapid evolution of evidence-based practice that parallels more widespread use of novel oral anticoagulants. This review concisely summarizes evidence-based guidelines for anticoagulant use in cardiovascular disease, and highlights new data specific to direct oral anticoagulants. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13171
Publisher Site
http://dx.doi.org/10.1111/ejh.13171DOI Listing
January 2019
7 Reads